Opus Genetics, Inc. (NASDAQ: IRD) has begun a Phase 1/2 clinical trial of its OPGx‑MERTK gene therapy for MERTK‑related retinitis pigmentosa in Abu Dhabi, United Arab Emirates. The trial is the first of its kind for this rare inherited retinal disease and marks a significant expansion of the company’s gene‑therapy pipeline.
The study employs an adeno‑associated virus (AAV) vector to deliver a functional copy of the MERTK gene directly to retinal cells. Clinical development activities are slated to commence in 2026 and are funded through Abu Dhabi’s Healthcare Research and Innovation Fund. The trial is conducted in partnership with the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, the Innovative Research Oversight and Support (IROS) division of the M42 group, and the Authority of Social Contribution – Ma’an, providing advanced imaging, surgical expertise, and a specialized retinal disease clinic.
MERTK mutations cause progressive loss of photoreceptor function, and no approved treatments currently exist for this condition. By initiating this trial, Opus expands its therapeutic reach to an estimated 60,000 patients worldwide and strengthens its position as a clinical‑stage leader in inherited retinal disease (IRD) treatments. The program builds on the company’s existing LCA5 and BEST1 pipelines, underscoring a focused strategy on AAV‑based gene therapies for rare eye disorders.
CEO George Magrath said the launch is a defining moment for patients and the field of inherited retinal disease, highlighting the partnership’s blend of scientific innovation, clinical excellence, and a shared commitment to addressing serious unmet needs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.